At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 506 enrolled
Drug / intervention
Elagolixdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
In Brief
A Phase 3 clinical trial evaluating Elagolix for Endometriosis. Completed, enrolled 506 participants.
Detailed Summary
A randomized study evaluating the continued safety and efficacy of elagolix in the management of moderate to severe endometriosis-associated pain in pre-menopausal women.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometriosis
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2012
First PostedJan 2013
Primary CompletionMay 2015
Study CompletionApr 2016
TodayJul 2026
First PostedJan 4, 2013
Enrollment StartDec 28, 2012
Primary CompletionMay 1, 2015
Study CompletionApr 15, 2016
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 13.5 years ago
Interventions
Elagolixdrug
Elagolix tablets administered orally